L218CAR19
- Generic Name
- L218CAR19
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06478381
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath